Diagnosis and treatment progress of chronic myeloid leukemia
10.3760/cma.j.issn.1009-9921.2020.01.002
- VernacularTitle: 慢性粒细胞白血病诊治进展
- Author:
Zhijian CAO
1
;
Jun MA
1
Author Information
1. Harbin Institute of Hematology and Oncology, Harbin 150010, China
- Publication Type:Review
- Keywords:
Leukemia, myelogenous, chronic, BCR-ABL positive;
Drug therapy, combination;
Tyrosine kinase inhibitor;
Digital polymerase chain reaction;
Discontinuation trial
- From:
Journal of Leukemia & Lymphoma
2020;29(1):6-8
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myeloid leukemia (CML) has made a milestone progress due to the development of the first generation tyrosine kinase inhibitor(TKI). Nowadays, most clinical trials in CML focus on discontinuation, even the second discontinuation, and the third generation TKI against T315I mutation. The conventional treatments are more focused on decreasing BCR-ABL transcripts rapidly. At the same time, the treatment management of some special patients has been valued.
